Clinical Trials in Pittsburgh

Showing 8101-8120 of 21,047 trials

A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma

NCT05358379

This is a 2-part, phase 1/2, open-label, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, pharmacogenomics, and efficacy of CYC140 administered orally daily. This study consists of Phase 1 and Phase 2 components in subjects with advanced solid tumors and lymphoma who have progressed despite having standard therapy or for which no standard therapy exists.

Solid Tumor, Adult Lymphoma

Cyclacel Pharmaceuticals, Inc.330 participantsStarted Apr 2022

Duarte, California, United States • Pittsburgh, Pennsylvania, United States • Houston, Texas, United States +2 more locations

COMPLETEDPhase 3< 1 mile

Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults

NCT04516746

The aim of the study is to assess the safety, efficacy, and immunogenicity of AZD1222 for the prevention of COVID-19.

COVID-19SARS-CoV-2

AstraZeneca32,450 participantsStarted Aug 2020

Phoenix, Arizona, United States • Scottsdale, Arizona, United States • Little Rock, Arkansas, United States +81 more locations

A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma

Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults

Find Trials by Condition in Pittsburgh

Pleconaril Enteroviral Sepsis Syndrome

ILLUMENATE Pivotal Post-Approval Study (PAS)

PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery

Blinded Dry Mouth Spray Crossover Study

Ascertaining the Radiologic Prognostic Importance of Extranodal Extension on Imaging (iENE) in Head and Neck Cancer

The Acute Burn ResUscitation Multicenter Prospective Trial

OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure

Evaluation of Real-World Data on the Performance of the TECNIS Odyssey™ IOL

Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent

A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations

Omnibond vs Dermabond

Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer

Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme

EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)

STAT: Standard Therapy Plus Active Therapy

A Pharmacokinetics Study of MK-7655A in Pediatric Participants With Gram-negative Infections (MK-7655A-020)

Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer

Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infection Due to MBL-producing Gram-negative Bacteria